ASPIBasic Materials · Chemicals

ASPI Stock Forecast: ASP Isotopes, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026

$4.27

−0.23% on the day

The 3 Wall Street analysts covering ASP Isotopes, Inc. hold a median 12-month price target of $13 — +204.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$537.6M

Ticker Nerd rank

14 / 100

Median analyst target

$13

Analysts covering

Total return, dividends reinvested

−3.6%

−9.1%

YTD

−20.2%

−59.6%

From 52W high

−69.6%

From 52W low

+20.6%

$14

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

ASPI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ASP Isotopes, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026

14 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions

Size

Growth

Accruals

Quality

Volatility

Momentum

Value

Issuance

Revisions (59): Analysts have, on balance, been raising their forecasts.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ASPI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ASPI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts

3 Buy0 Hold0 Sell

Low $11Median $13High $15

The green dot is the last close — the median target sits +204.4% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
14 Apr 2026	Canaccord Genuity	Maintains	Buy	$11
4 Dec 2025	Cantor Fitzgerald	Initiates	Overweight	—
24 Nov 2025	Canaccord Genuity	Maintains	Buy	—
17 Sept 2025	Canaccord Genuity	Maintains	Buy	—
21 May 2025	Canaccord Genuity	Maintains	Buy	—
18 Oct 2024	Canaccord Genuity	Maintains	Buy	—
4 Oct 2024	Canaccord Genuity	Initiates	Buy	—
7 Aug 2024	HC Wainwright & Co.	Maintains	Buy	—
17 Apr 2024	HC Wainwright & Co.	Maintains	Buy	—
29 Feb 2024	HC Wainwright & Co.	Maintains	Buy	—
5 Dec 2023	HC Wainwright & Co.	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ASPI appears on the weeks it earns a place.

Estimates

ASPI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

ASP Isotopes, Inc. (ASPI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −2.0×
Price / sales: 20.0×
Price / book: 1.9×
EV / EBITDA: −7.4×

Growth & margins

Revenue growth (YoY): 279.3%
Earnings growth (YoY): 279.4%
Gross margin: 39.9%
Operating margin: −595.4%
Net margin: 14.3%

Returns & dividend

Return on equity: −103.3%
Return on assets: −13.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ASPI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelChemicals

Company	Market cap	TKN rank
ASPIASP Isotopes, Inc.	$537.6M	14
RYAMRayonier Advanced Materials, Inc.	$569.6M	55
ASIXAdvansix, Inc.	$459.4M	34
VHIValhi, Inc.	$458.8M	48
LXULSB Industries, Inc.	$736.0M	96
TROXTronox Holdings plc	$950.7M	26
GPREGreen Plains, Inc.	$1.1B	99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ASP Isotopes, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ASPI news & analysis

ASP Isotopes Targets 2026 Deliveries as Helium, Radiopharmacy Expansion Gains Speed

MarketBeat · 12 Aug 2026positive

ASP Isotopes presented expansion plans for its isotope production, radiopharmacy, and helium businesses at the Canaccord Genuity 46th Annual Growth Conference. The company said it expects commercial deliveries of several stable isotopes to begin in the second half of 2026.

Why it matters — The 2026 delivery target gives ASPI watchers a concrete timeline for when the company's production expansion is expected to start generating commercial revenue.

ASP Isotopes Inc. Announces that Renergen Limited's Subsidiary has Entered into a Take-or-Pay Contract for the Supply of Liquified Natural Gas to Be Produced at the Virginia Gas Project in South Africa

GlobeNewsWire · 6 Aug 2026positive

Tetra4, a Renergen subsidiary and developer of the Virginia Gas Project, has entered into an additional take-or-pay contract to supply liquefied natural gas to a domestic food processor. This establishes multi-year contracted cash flow supporting Phase 1 commercial operations, which remain targeted for completion in the third quarter of 2026.

Why it matters — ASPI watchers follow this because the new take-or-pay contract helps firm up contracted cash flow for the Virginia Gas Project's Phase 1 operations, which remain on track for completion in Q3 2026.

ASP Isotopes to Participate in Citi's 2026 Natural Resources Conference

GlobeNewsWire · 5 Aug 2026neutral

ASP Isotopes Inc. announced it will host investor meetings at Citi's 2026 Natural Resources Conference on Thursday, August 13, 2026, in Las Vegas, Nevada. The company described itself as an advanced materials company focused on developing technologies and processes for producing critical materials used across multiple industries.

Why it matters — An ASP Isotopes watcher would care because conference investor meetings give management a forum to present the company's technology and processes to institutional investors and broaden its visibility in the natural resources sector.

Aeternum Health Announces Change in Strategy, New Management, and Updates Investors on Progress

MCAP MediaWire · 4 Aug 2026neutral

Aeternum Health (OTC: AETN) announced a change in strategy, new management, and provided investors with an update on its corporate progress. The announcement was made in Washington, D.C. and distributed via PRISM MediaWire.

Why it matters — This item concerns Aeternum Health, not ASP Isotopes, Inc., so it has no direct bearing on ASPI's outlook.

ASP Isotopes Issues Letter to Shareholders

GlobeNewsWire · 4 Aug 2026positive

ASP Isotopes issued a shareholder letter from Executive Chairman and CEO Paul Mann ahead of its Q2 2026 results, stating that all business units are making progress, group revenues are increasing, and three units appear to be at an inflection point expected to contribute to near-term profitability. The letter also noted that its global PET Labs group grew organic revenue by over 50% in 1H 2026 compared with 1H 2025.

Why it matters — The letter provides ASPI watchers with management's latest update on business performance and the company's path toward profitability ahead of the upcoming quarterly results.

FAQ

Frequently asked questions about ASPI stock

What is the ASPI stock price forecast for 2026-2027?

The 3 Wall Street analysts covering ASP Isotopes, Inc. have a median 12-month price target of $13, with estimates ranging from $11 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ASPI stock a buy right now?

Of the 3 analysts covering ASP Isotopes, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ASP Isotopes, Inc. 14 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ASPI?

As at 15 Aug 2026, ASP Isotopes, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (59 of 100).

Will ASPI stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +204.4% from the last close, and Ticker Nerd's factor model ranks ASP Isotopes, Inc. 14 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ASPI stock forecast for 2030?

No analyst covering ASP Isotopes, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASPI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $15 over the next 12 months.

How has ASPI stock performed over the past year?

ASP Isotopes, Inc. returned -59.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ASP Isotopes, Inc. do?

ASP Isotopes Inc. is an advanced materials company specializing in the enrichment and production of scarce, high-value isotopes for industrial and scientific applications.

What is the latest news on ASPI?

The most recent item we track (MarketBeat, 12 Aug 2026): "ASP Isotopes Targets 2026 Deliveries as Helium, Radiopharmacy Expansion Gains Speed". ASP Isotopes presented expansion plans for its isotope production, radiopharmacy, and helium businesses at the Canaccord Genuity 46th Annual Growth Conference. The company said it expects commercial deliveries of several stable isotopes to begin in the second half of 2026.

Company

About ASP Isotopes, Inc.

ASP Isotopes Inc. is an advanced materials company specializing in the enrichment and production of scarce, high-value isotopes for industrial and scientific applications. The company focuses on providing enriched isotopes used in nuclear medicine and therapeutics, next-generation semiconductors, green energy generation, quantum computing, and advanced nuclear fuels. ASP Isotopes Inc. employs proprietary Aerodynamic Separation Process technology and related enrichment methods to handle elements across low and high atomic masses, enabling the production of isotopes that are difficult to process with conventional techniques. Its operations are structured around nuclear fuels and specialist isotopes and related services, supporting customers that require high-purity materials for radiopharmaceutical inputs, diagnostic imaging, specialty chip manufacturing, and emerging quantum technologies. Incorporated in 2021 and headquartered in Washington, D.C., the company’s manufacturing and enrichment activities are centered in South Africa, serving a global customer base in highly specialized, regulated end markets.

CEO Mr. Paul Elliot Mann C.F.A. · 271 employees · United States · https://aspisotopes.com